Growth Hormone SecretagoguesWADA Prohibited
CJC-1295 With DAC
Synonyms: DAC:GRF, Drug Affinity Complex GHRH, CJC-1295
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Maleimidopropionyl)-NH2
Critical Safety & Regulatory Notice
CJC-1295 With DAC is classified as a regulated, unapproved, or research-only substance. Doping/Regulatory Status: Not FDA approved. Strictly prohibited by WADA under Section S2.. Clinical safety profiles for human use are deficient or not approved.
History & Discovery Timeline
CJC-1295 With DAC was developed by ConjuChem in 2005. The Drug Affinity Complex (DAC) allows covalent bonding to serum albumin, extending half-life up to 8 days.
What it is: It is a GHRH analog containing a Drug Affinity Complex (DAC) attachment, which significantly increases its half-life. It is classified as a Metabolic peptide.
Proposed Mechanisms & Research Findings: It binds to albumin to extend its circulation, providing continuous stimulation of pituitary GHRH receptors and elevated baseline growth hormone levels.
Regulatory & Safety Status: It is not FDA approved. Sourcing online carries significant regulatory and safety risks due to potential contamination and dosage inconsistencies.
Athletic & Anti-Doping Status: Strictly prohibited by WADA under Section S2 as a growth hormone releasing hormone. Banned in- and out-of-competition.
Understanding CJC-1295 With DAC Key Facts
Primary Target System:NEUROENDOCRINE
Residue Count / Length:32 Amino Acids
Primary Action & Category:GHRH Receptor Agonist (Extended Half-life) (Growth Hormone Secretagogues)
Primary Receptors:GHRH Receptor (GHRHR), Serum Albumin Binding Complex
Figure 1: Detailed molecular mechanism pathways of CJC-1295 With DAC (click to enlarge).